[
  {
    "ts": "2026-02-09T09:13:34+00:00",
    "headline": "Novo Nordisk shares rise as Hims abandons $49 weight-loss pill",
    "summary": "COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of ​a $49 weight-loss pill over the weekend, following legal threats from ‌Novo and the U. Hims introduced the compounded pill based on semaglutide - ‌a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
      "content": {
        "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
        "contentType": "STORY",
        "title": "Novo Nordisk shares rise as Hims abandons $49 weight-loss pill",
        "description": "",
        "summary": "COPENHAGEN, Feb 9 () - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of ​a $49 weight-loss pill over the weekend, following legal threats from ‌Novo and the U. Hims introduced the compounded pill based on semaglutide - ‌a key ingredient in Novo's blockbuster drugs Wegovy and Ozempic - last Thursday, prompting pushback from the Danish drugmaker and regulatory authorities.",
        "pubDate": "2026-02-09T09:13:34Z",
        "displayTime": "2026-02-09T09:13:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/169cee0bf3615c357bb727c349a37c1f",
          "originalWidth": 800,
          "originalHeight": 527,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q5tu47T4jLBH.vaRgG7MVg--~B/aD01Mjc7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/169cee0bf3615c357bb727c349a37c1f.cf.webp",
              "width": 800,
              "height": 527,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jfLTpFgNiIdojq6eRefROQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/169cee0bf3615c357bb727c349a37c1f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T05:57:00+00:00",
    "headline": "Innovent Biologics Strikes Partnership Deal With Eli Lilly",
    "summary": "Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.",
    "url": "https://www.wsj.com/tech/biotech/innovent-biologics-strikes-partnership-deal-with-eli-lilly-fa6713f9?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ac224973-802c-35d2-b975-9398f85a9adb",
      "content": {
        "id": "ac224973-802c-35d2-b975-9398f85a9adb",
        "contentType": "STORY",
        "title": "Innovent Biologics Strikes Partnership Deal With Eli Lilly",
        "description": "",
        "summary": "Chinese drugmaker Innovent Biologics and Eli Lilly plan to target cancer and immune system diseases under the partnership.",
        "pubDate": "2026-02-09T05:57:00Z",
        "displayTime": "2026-02-09T05:57:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ac224973-802c-35d2-b975-9398f85a9adb/innovent-biologics-strikes.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6914d8a6fb87a081fde515b59bae8642",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LXMe.ymKL_eN79CDkj2a9w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6914d8a6fb87a081fde515b59bae8642.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ciE_MH1eMDoSTjrzHtPh1w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6914d8a6fb87a081fde515b59bae8642.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/tech/biotech/innovent-biologics-strikes-partnership-deal-with-eli-lilly-fa6713f9?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IVBIY"
            },
            {
              "symbol": "IVBXF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T11:36:51+00:00",
    "headline": "Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why",
    "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
    "url": "https://www.investors.com/news/technology/hims-hers-health-stops-offering-knockoff-wegovy-pill-fda-crackdown/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "1002bb24-5eb4-303a-9144-64abe04a7a40",
      "content": {
        "id": "1002bb24-5eb4-303a-9144-64abe04a7a40",
        "contentType": "STORY",
        "title": "Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why",
        "description": "",
        "summary": "Hims & Hers backed down under FDA pressure two days just after launching the copycat version of Novo Nordisk's weight-loss pill.",
        "pubDate": "2026-02-09T11:36:51Z",
        "displayTime": "2026-02-09T11:36:51Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1002bb24-5eb4-303a-9144-64abe04a7a40/hims-hers-halts-knockoff.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6cfe027a47fbde4d7312dced314aff0b",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3O3uCGa3Xeq_MEs22jdHiA--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6cfe027a47fbde4d7312dced314aff0b.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pXxP9EU.MV8rjo4qP_AZ6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6cfe027a47fbde4d7312dced314aff0b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/hims-hers-health-stops-offering-knockoff-wegovy-pill-fda-crackdown/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T11:01:26+00:00",
    "headline": "Innovent and Lilly to advance new oncology and immunology medicines",
    "summary": "Innovent will receive an upfront payment of $350m under the agreement.",
    "url": "https://www.pharmaceutical-technology.com/news/innovent-lilly-oncology-immunology-medicines/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "51b5b7c4-3612-3e75-baf4-634022fe74da",
      "content": {
        "id": "51b5b7c4-3612-3e75-baf4-634022fe74da",
        "contentType": "STORY",
        "title": "Innovent and Lilly to advance new oncology and immunology medicines",
        "description": "",
        "summary": "Innovent will receive an upfront payment of $350m under the agreement.",
        "pubDate": "2026-02-09T11:01:26Z",
        "displayTime": "2026-02-09T11:01:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/e614c70ad9a5dd9b5dcfdbfe505debec",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Lilly will hold exclusive rights to develop and commercialise the programmes outside Greater China. Credit: Tada Images / Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FX.zvlGi.f9_JeOu6nEe8A--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/e614c70ad9a5dd9b5dcfdbfe505debec.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KXKsQ7DfZB7py4t8rztnOQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/e614c70ad9a5dd9b5dcfdbfe505debec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/innovent-lilly-oncology-immunology-medicines/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/innovent-lilly-advance-oncology-immunology-110126837.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IVBIY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T10:49:22+00:00",
    "headline": "Novo Nordisk surges as Hims pulls $49 weight loss pill under FDA pressure",
    "summary": "COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of a $49 copy of a weight-loss pill following legal threats from the ​Danish group and the U. The gains pushed Novo's shares higher than before Hims announced ‌its non-FDA-approved version of Novo's semaglutide as investors perceived the FDA actions as a broader crackdown on compounded GLP-1 drugs, which could reduce competitive threats ‌to branded treatments,",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
      "content": {
        "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
        "contentType": "STORY",
        "title": "Novo Nordisk surges as Hims pulls $49 weight loss pill under FDA pressure",
        "description": "",
        "summary": "COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk's shares jumped more than 8% on Monday after telehealth firm Hims & Hers cancelled the launch of a $49 copy of a weight-loss pill following legal threats from the ​Danish group and the U. The gains pushed Novo's shares higher than before Hims announced ‌its non-FDA-approved version of Novo's semaglutide as investors perceived the FDA actions as a broader crackdown on compounded GLP-1 drugs, which could reduce competitive threats ‌to branded treatments,",
        "pubDate": "2026-02-09T10:49:22Z",
        "displayTime": "2026-02-09T10:49:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/9cb75f20-05a2-11f1-bf97-4d2d6778d96c",
          "originalWidth": 4448,
          "originalHeight": 2911,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/su9pm8YI6lLwNbzBqOF_Ow--~B/aD0yOTExO3c9NDQ0ODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/9cb75f20-05a2-11f1-bf97-4d2d6778d96c.cf.webp",
              "width": 4448,
              "height": 2911,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pThKw72ZHlLccJT5LV59Vg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/9cb75f20-05a2-11f1-bf97-4d2d6778d96c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T13:07:45+00:00",
    "headline": "Novo Nordisk sues Hims over scrapped $49 weight-loss pill copy",
    "summary": "COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk sued Hims and Hers Health on Monday over patent infringement after the U. telehealth firm launched, then cancelled, a $49 copy of Novo's weight-loss pill Wegovy following backlash from the U.",
    "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
      "content": {
        "id": "eba1a6c5-1069-3b02-9249-bb65961b531a",
        "contentType": "STORY",
        "title": "Novo Nordisk sues Hims over scrapped $49 weight-loss pill copy",
        "description": "",
        "summary": "COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk sued Hims and Hers Health on Monday over patent infringement after the U. telehealth firm launched, then cancelled, a $49 copy of Novo's weight-loss pill Wegovy following backlash from the U.",
        "pubDate": "2026-02-09T13:07:45Z",
        "displayTime": "2026-02-09T13:07:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/6442b2cd483ff58c06265f8cc7742d06",
          "originalWidth": 800,
          "originalHeight": 527,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PZBBnZmdOYlNatk_bCEitg--~B/aD01Mjc7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6442b2cd483ff58c06265f8cc7742d06.cf.webp",
              "width": 800,
              "height": 527,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s_iv1jzQesLYqedbwA6AAA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/6442b2cd483ff58c06265f8cc7742d06.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://uk.finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "GB",
          "lang": "en-GB"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-shares-rise-hims-074530459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T12:29:49+00:00",
    "headline": "Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal",
    "summary": "Lilly partners with Innovent on new cancer and immune therapies, with potential milestones reaching $8.5 billion.",
    "url": "https://finance.yahoo.com/news/eli-lilly-pays-350-million-122949729.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "8cac6ed9-5341-3411-8043-e61f21c2d0b9",
      "content": {
        "id": "8cac6ed9-5341-3411-8043-e61f21c2d0b9",
        "contentType": "STORY",
        "title": "Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal",
        "description": "",
        "summary": "Lilly partners with Innovent on new cancer and immune therapies, with potential milestones reaching $8.5 billion.",
        "pubDate": "2026-02-09T12:29:49Z",
        "displayTime": "2026-02-09T12:29:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-pays-350-million-122949729.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-pays-350-million-122949729.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T12:09:42+00:00",
    "headline": "Lilly to buy Orna Therapeutics for up to $2.4 billion",
    "summary": "Feb 9 () - ​Eli ‌Lilly will ‌acquire therapy developer ⁠Orna ‌Therapeutics for ‍up to $2.4 ​billion ‌in cash, the companies said ⁠on ​Monday.",
    "url": "https://finance.yahoo.com/news/lilly-buy-orna-therapeutics-2-120647594.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "5fa5d140-6f69-3d1f-b2ce-4ad976e28c3c",
      "content": {
        "id": "5fa5d140-6f69-3d1f-b2ce-4ad976e28c3c",
        "contentType": "STORY",
        "title": "Lilly to buy Orna Therapeutics for up to $2.4 billion",
        "description": "",
        "summary": "Feb 9 () - ​Eli ‌Lilly will ‌acquire therapy developer ⁠Orna ‌Therapeutics for ‍up to $2.4 ​billion ‌in cash, the companies said ⁠on ​Monday.",
        "pubDate": "2026-02-09T12:09:42Z",
        "displayTime": "2026-02-09T12:09:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/88067dcdf26eb7cd865b0351e7cf4761",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W4xEEapkjl_F8UjQkAXuEQ--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/88067dcdf26eb7cd865b0351e7cf4761.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cRAN5AhV92dlokNCx_tIdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/88067dcdf26eb7cd865b0351e7cf4761.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-buy-orna-therapeutics-2-120647594.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-buy-orna-therapeutics-2-120647594.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T12:00:00+00:00",
    "headline": "Lilly to acquire Orna Therapeutics to advance cell therapies",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.",
    "url": "https://finance.yahoo.com/news/lilly-acquire-orna-therapeutics-advance-120000426.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "dcfd5072-9ddc-32d4-af3b-f8f883e5a79f",
      "content": {
        "id": "dcfd5072-9ddc-32d4-af3b-f8f883e5a79f",
        "contentType": "STORY",
        "title": "Lilly to acquire Orna Therapeutics to advance cell therapies",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.",
        "pubDate": "2026-02-09T12:00:00Z",
        "displayTime": "2026-02-09T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/df345efe9aaf8625c1224e8763d43e53",
          "originalWidth": 400,
          "originalHeight": 124,
          "caption": "(PRNewsfoto/Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dqh2.OUhDnbMQOuq0T.AIQ--~B/aD0xMjQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/df345efe9aaf8625c1224e8763d43e53.cf.webp",
              "width": 400,
              "height": 124,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wwDB4ilF3A4GGRE1cktfIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/df345efe9aaf8625c1224e8763d43e53.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-acquire-orna-therapeutics-advance-120000426.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-acquire-orna-therapeutics-advance-120000426.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T11:46:52+00:00",
    "headline": "Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill",
    "summary": "Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators.  Shares in Novo Nordisk jumped more than 7% in Denmark.  The stock also trades in the U.S. as an American depositary receipt with the ticker NVO.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-09-2026/card/novo-nordisk-stock-jumps-after-hims-hers-scraps-copycat-weight-loss-pill-CXu10oIH4vMHTcJywENv?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cabf0cf8-9df4-351b-9a4c-759ff5bfe04d",
      "content": {
        "id": "cabf0cf8-9df4-351b-9a4c-759ff5bfe04d",
        "contentType": "STORY",
        "title": "Novo Nordisk Stock Soars After Hims & Hers Scraps Copycat Weight-Loss Pill",
        "description": "",
        "summary": "Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators.  Shares in Novo Nordisk jumped more than 7% in Denmark.  The stock also trades in the U.S. as an American depositary receipt with the ticker NVO.",
        "pubDate": "2026-02-09T11:46:52Z",
        "displayTime": "2026-02-09T11:46:52Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cabf0cf8-9df4-351b-9a4c-759ff5bfe04d/novo-nordisk-stock-soars.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-09-2026/card/novo-nordisk-stock-jumps-after-hims-hers-scraps-copycat-weight-loss-pill-CXu10oIH4vMHTcJywENv?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T11:42:57+00:00",
    "headline": "Lilly Deepens Longtime Innovent Partnership",
    "summary": "Cancer and immunology programs take focus",
    "url": "https://finance.yahoo.com/news/lilly-deepens-longtime-innovent-partnership-114257054.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "fe93da76-c0b5-3aae-b208-1714b4e6f3d5",
      "content": {
        "id": "fe93da76-c0b5-3aae-b208-1714b4e6f3d5",
        "contentType": "STORY",
        "title": "Lilly Deepens Longtime Innovent Partnership",
        "description": "",
        "summary": "Cancer and immunology programs take focus",
        "pubDate": "2026-02-09T11:42:57Z",
        "displayTime": "2026-02-09T11:42:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-deepens-longtime-innovent-partnership-114257054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-deepens-longtime-innovent-partnership-114257054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IVBIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]